Lantern Pharma Inc.
LTRN
$3.76
-$0.17-4.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.36% | -6.89% | -14.54% | -17.18% | -8.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.00% | 4.20% | 33.73% | 27.47% | 64.25% |
| Operating Income | -47.00% | -4.20% | -33.73% | -27.47% | -64.25% |
| Income Before Tax | -42.52% | -4.49% | -40.67% | -23.80% | -39.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.52% | -4.49% | -40.67% | -23.80% | -39.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.52% | -4.49% | -40.67% | -23.80% | -39.60% |
| EBIT | -47.00% | -4.20% | -33.73% | -27.47% | -64.25% |
| EBITDA | -47.03% | -4.19% | -33.74% | -27.46% | -64.30% |
| EPS Basic | -43.75% | -5.44% | -42.20% | -25.24% | -39.40% |
| Normalized Basic EPS | -43.74% | -5.45% | -40.74% | -25.28% | -39.36% |
| EPS Diluted | -43.75% | -5.44% | -42.20% | -26.04% | -38.67% |
| Normalized Diluted EPS | -43.74% | -5.45% | -40.74% | -25.28% | -39.36% |
| Average Basic Shares Outstanding | -0.87% | -0.90% | -1.05% | -1.14% | 0.17% |
| Average Diluted Shares Outstanding | -0.87% | -0.90% | -1.05% | -1.14% | 0.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
